Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature
- PMID: 32388880
- PMCID: PMC7273104
- DOI: 10.1111/jns.12382
Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature
Abstract
Acute demyelinating inflammatory polyneuropathy (AIDP) is the most common type of Guillain-Barré syndrome (GBS) in Europe, following several viral and bacterial infections. Data on AIDP-patients associated with SARS-CoV-2 (coronavirus-2) infection are scarce. We describe the case of a 54-years-old Caucasian female patient with typical clinical and electrophysiological manifestations of AIDP, who was reported positive with PCR for SARS-CoV-2, 3 weeks prior to onset of the neurological symptoms. She did not experience a preceding fever or respiratory symptoms, but a transient loss of smell and taste. At the admission to our neurological department, a progressive proximally pronounced paraparesis, areflexia, and sensory loss with tingling of all extremities were found, which began 10 days before. The modified Erasmus Giullain-Barré Syndrome outcome score (mEGOS) was 3/9 at admission and 1/12 at day 7 of hospitalization. The electrophysiological assessment proved a segmental demyelinating polyneuropathy and cerebrospinal fluid examination showed an albuminocytologic dissociation. The neurological symptoms improved significantly during treatment with immunoglobulins. Our case draws attention to the occurrence of GBS also in patients with COVID-19 (coronavirus disease 2019), who did not experience respiratory or general symptoms. It emphasizes that SARS-CoV-2 induces immunological processes, regardless from the lack of prodromic symptoms. However, it is likely that there is a connection between the severity of the respiratory syndrome and further neurological consequences.
Keywords: COVID-19; Guillain-Barré syndrome; SARS-CoV2.
© 2020 Peripheral Nerve Society.
Figures
Similar articles
-
A Case of Guillain-Barré Syndrome Associated With COVID-19.J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620961198. doi: 10.1177/2324709620961198. J Investig Med High Impact Case Rep. 2020. PMID: 32981333 Free PMC article.
-
Guillain-Barré Syndrome with Facial Diplegia Related to SARS-CoV-2 Infection.Can J Neurol Sci. 2020 Nov;47(6):852-854. doi: 10.1017/cjn.2020.106. Epub 2020 May 29. Can J Neurol Sci. 2020. PMID: 32468972 Free PMC article. No abstract available.
-
Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic.J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1105-1110. doi: 10.1136/jnnp-2020-324491. Epub 2020 Aug 27. J Neurol Neurosurg Psychiatry. 2020. PMID: 32855289
-
Spectrum of Neurological Manifestations in Covid-19: A Review.Neurol India. 2020 May-Jun;68(3):560-572. doi: 10.4103/0028-3886.289000. Neurol India. 2020. PMID: 32643664 Review.
-
COVID-19-associated Guillain-Barré syndrome: The early pandemic experience.Muscle Nerve. 2020 Oct;62(4):485-491. doi: 10.1002/mus.27024. Epub 2020 Aug 11. Muscle Nerve. 2020. PMID: 32678460 Free PMC article. Review.
Cited by
-
Relation between Guillain-Barré syndrome and Covid-19: Case-Series.J Med Life. 2023 Sep;16(9):1433-1435. doi: 10.25122/jml-2023-0275. J Med Life. 2023. PMID: 38107719 Free PMC article.
-
Neurological complications after COVID-19: A narrative review.eNeurologicalSci. 2023 Nov 15;33:100485. doi: 10.1016/j.ensci.2023.100485. eCollection 2023 Dec. eNeurologicalSci. 2023. PMID: 38077923 Free PMC article. Review.
-
A clinical approach to the investigation and management of long COVID associated neuropathic pain.Eur Arch Psychiatry Clin Neurosci. 2023 Dec 8. doi: 10.1007/s00406-023-01721-8. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 38063895 Review.
-
Guillain-Barre syndrome in patients with coronavirus disease-2019: Report of six cases and review of literature.Curr J Neurol. 2020 Jul 5;19(3):122-130. doi: 10.18502/cjn.v19i3.5425. Curr J Neurol. 2020. PMID: 38011403 Free PMC article.
-
Reccurent guillain barré syndrome after COVID-19.Neurosciences (Riyadh). 2023 Oct;28(4):273-276. doi: 10.17712/nsj.2023.4.20230012. Neurosciences (Riyadh). 2023. PMID: 37844949 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
